IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report
6.11.2025 14:00:00 CET | Business Wire | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains
IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives.
The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders.
With operations in more than 50 countries and partnerships with 18,000 growers and 300 retailers, IFCO’s scale enables measurable impact from decarbonizing supply chains to reducing food waste. By combining innovation, strong governance, and its proven circular model, IFCO demonstrates how reusable packaging can deliver long-term value not only for customers but also for society and the environment.
Mike Pooley, CEO of IFCO, said, “The success of our ESG strategy shows how sustainability and strong business performance can go hand in hand. By embedding ESG into every decision, we’ve helped build a more resilient, customer-focused business. Our work is not just about driving strong business results, it is about creating real-world impact, including less waste, greater efficiency, and stronger communities wherever we operate.”
IFCO’s global contribution to evolving regulatory frameworks
In Europe, IFCO’s model directly supports compliance with the new Packaging and Packaging Waste Regulation (PPWR) and food waste reduction targets under the revised Waste Framework Directive. This positions IFCO’s reusable packaging as an essential tool for meeting mandatory reuse goals. In the United States, where Extended Producer Responsibility (EPR) legislation is rapidly expanding at the state level, IFCO offers retailers and growers a cost-effective, compliance-ready alternative to disposable packaging. And globally, as markets from Latin America to Asia embrace circular supply chains, IFCO’s scale and proven track record make it a trusted partner for businesses seeking resilient, low-carbon packaging solutions.
Key results of IFCOs 2025 sustainability strategy
- 10+ billion single-use boxes eliminated since 2021.
- 3.2 million tonnes of customer CO2 emissions avoided
- 93% landfill diversion rate
- 37% reduction in emissions per crate
- 10% reduction in water used per crate
- 100% renewable electricity achieved at all IFCO sites.
- ISO 9001, 14001 and 45001 certifications achieved globally, underpinning best-in-class governance.
- 7 new reusable products launched, including reusable pallets and fish crates.
- 440,000+ RPCs donated to food banks globally, supporting communities.
- Record employee satisfaction and Investors in People accreditation.
Reflecting on the milestone, Iñigo Canalejo, Vice President of ESG and Strategic Marketing at IFCO, said: “Over the past five years, we have advanced our ESG journey and achieved most of our goals. More importantly, we’ve built a stronger, more sustainable business together with our people and partners. ESG is now truly embedded in everything we do, helping us thrive as a company while creating value for the planet and society.”
Impact of the IFCO SmartCycle in FY25
During FY2025 (July 1, 2024 – June 30, 2025), IFCO’s SmartCycle™ circular model continued to deliver significant environmental benefits. Compared to single-use packaging, IFCO RPCs reduce CO₂e emissions by up to 62%, water use by up to 69%, and solid waste by up to 96%.
Across all markets, IFCO customers collectively achieved:
- 734,766 metric tonnes of CO₂e emissions saved – equivalent to circling the planet 149,341 times by car
- 55,197 megaliters of water saved – equal to 22,079 Olympic-sized swimming pools
- 68,706 tonnes of food waste avoided – equivalent to 110 million meals
The full IFCO ESG Report 2025 is available here: https://www.ifco.com/about-ifco/sustainability/esg-report-2025/
About IFCO
IFCO is a leading global provider of reusable packaging solutions for fresh foods, empowering customers to participate in the circular economy in 50+ countries. IFCO operates a pool of over 400 million reusable packaging containers (RPCs) globally, which are used for over 2.5 billion shipments of fresh fruits and vegetables, meat, poultry, seafood, eggs, bread, and other items from suppliers to grocery retailers every year. IFCO RPCs ensure a better fresh food supply chain by protecting freshness and quality and lowering costs, food waste and environmental impact compared to single-use packaging. More: www.ifco.com | Follow us on LinkedIn @IFCO SYSTEMS
View source version on businesswire.com: https://www.businesswire.com/news/home/20251106324273/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom